Latest Breaking News On - Alina jucov - Page 1 : comparemela.com

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A.

United statesJean pierre sommadossiJonae barnesQi huangAlina jucovAtea pharmaceuticals incGlobenewswire incCorporate communicationsAtea pharmaceuticalsEuropean association for the studyWhile the companyInclude new antiviral efficacy resultsLead in cohortOngoing phaseAlso highlightHigh prevalence

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-In-Class Combination Profile Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis

Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also H

United statesAlina jucovQi huangJonae barnesJean pierre sommadossiCorporate communicationsWhile the companyAtea pharmaceuticalsAtea pharmaceuticals incFounder of atea pharmaceuticals weInclude new antiviral efficacy resultsLead in cohortOngoing phaseAlso highlightHigh prevalenceResistance associated substitutions

Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023

Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Jin hongCorey davisYannick debingLawrence blattAlina jucovKusum guptaJinlin houVeronica eamesTongfei wuLifesci communicationsExchange commissionExchange commission onAligos therapeutics incAligos therapeuticsEuropean associationScientific presentations

Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023

Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jinlin houKusum guptaVeronica eamesLawrence blattYannick debingCorey davisAlina jucovTongfei wuJin hongAligos therapeutics incLifesci communicationsExchange commission onExchange commissionEuropean associationScientific presentationsLate breaking poster

Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023 - Aligos Therapeutics (NASDAQ:ALGS)

-Presentations include a late breaking poster from an ongoing Phase 1b study of ALG-000184 demonstrating multi-log reductions in HBsAg, DNA, and RNA levels in subjects dosed for up to 36 weeks- -Data collectively

Corey davisLawrence blattTongfei wuJinlin houVeronica eamesYannick debingKusum guptaAlina jucovJin hongExchange commission onLifesci communicationsAligos therapeutics incExchange commissionEuropean associationScientific presentationsLate breaking poster